Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$131.82

0.29 (0.22%)

, BAYRY

Bayer

$133.06

0.01 (0.01%)

06:04
06/13/17
06/13
06:04
06/13/17
06:04

Bayer, J&J cleared of liability in second Xarelto trial, Reuters reports

Bayer (BAYRY) and Johnson & Johnson (JNJ) have been cleared of liability by a federal jury in the second trial stemming from thousands of lawsuits blaming injuries on Xarelto, a blood thinning drug, Reuters reports. Reference Link

JNJ

Johnson & Johnson

$131.82

0.29 (0.22%)

BAYRY

Bayer

$133.06

0.01 (0.01%)

  • 13

    Jun

  • 15

    Jun

  • 26

    Jun

JNJ Johnson & Johnson
$131.82

0.29 (0.22%)

06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Tesaro prostate study suspension due to fast enrollment, says Credit Suisse
After speaking to Tesaro (TSRO), after they spoke to their partner Johnson & Johnson (JNJ), Credit Suisse analyst Alethia Young said the news of the companies' suspension of participant recruitment in the study of niraparib in prostate cancer is actually positive, since it is due to the trial enrolling faster than expected. The suspension has nothing to do with safety or efficacy and is not a clinical hold, but is due to having too many patients in the first part of trial, Young was told. She maintains an Outperform rating on Tesaro shares.
06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
BAYRY Bayer
$133.06

0.01 (0.01%)

01/06/17
JPMS
01/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares are mispriced, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says Monsanto (MON) shares are mispriced and offer an attractive risk/reward proposition. A first catalyst for the shares would be regulatory agreement in the Dow Chemical (DOW)/DuPont (DD) transaction, Zekauskas tells investors in a research note. The analyst thinks a favorable resolution to the Dow/DuPont merger would be seen as improving the probability of the success of the Bayer/Monsanto transaction. He notes that Bayer has agreed to purchase Monsanto for $128 per share in cash, which represents 21% appreciation potential should the deal close by year-end. Zekauskas thinks a "reasonable floor" price for Monsanto shares, should the deal fail, is $102. He keeps an Overweight rating on the name with a $128 price target.
03/03/17
JPMS
03/03/17
NO CHANGE
Target $128
JPMS
Overweight
EU approvals of other ag deals may narrow Monsanto deal spread, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas said commentary from the CEOs of DuPont (DD) and Syngenta (SYT) and press reports from Europe suggest that their deals with Dow Chemical (DOW) and ChemChina, respectively, are likely to be approved. Approvals from Europe for those deals may "trigger a meaningful closing of the arbitrage spread" in Monsanto (MON) shares versus Bayer's (BAYRY) offer price, Zekauskas tells investors. He recommends buying Monsanto shares at current levels for this reason, adding that he believes the shares would only fall about 2.5%, or down to $112, in the event of the Bayer deal falling through. Zekauskas keeps an Overweight rating and $128 price target on Monsanto shares, which closed yesterday at just below $115 per share.
04/06/17
JPMS
04/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares offer 'excellent' risk/reward proposition, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says shares of Monsanto (MON) at current levels offer an "excellent" risk/reward proposition. The analyst views capital appreciation potential to the end of 2017 as 11% or a 15% annual return. He sees downside risk of only 3%, to $112 per share, in the event that Bayer (BAYRY) is not able to consummate the acquisition. Zekauskas has increased confidence in the deal closing following recent regulatory rulings and keeps an Overweight rating on the name with a $128 price target.
04/10/17
PIPR
04/10/17
NO CHANGE
Target $17
PIPR
Overweight
OncoMed price target lowered to $17 from $26 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for OncoMed (OMED) to $17 from $26 following two negative announcements, namely that the Phase II YOSEMITE study of demcizumab in first line pancreatic cancer failed and Bayer (BAYRY) returned rights for ipafricept and vantictumab. The analyst also notes that now partner Celgene (CELG) will review all data on demcizumab including Phase II DENALI non-small cell lung cancer data and Phase Ib combo data with KEYTRUDA, although he does not expect Celgene to exercise its option. Tenthoff reiterates an Overweight rating on OncoMed's shares.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$347.49

-14.69 (-4.06%)

21:14
06/21/18
06/21
21:14
06/21/18
21:14
Periodicals
Tesla job cuts to concentrate on the solar facilities, Reuters says »

As part of the 9% staff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

ECOR

ElectroCore

$0.00

(0.00%)

21:08
06/21/18
06/21
21:08
06/21/18
21:08
Syndicate
ElectroCore 5.2M share IPO priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

TELNY

Telenor

$0.00

(0.00%)

20:43
06/21/18
06/21
20:43
06/21/18
20:43
Upgrade
Telenor rating change at JPMorgan »

Telenor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$71.05

-1.77 (-2.43%)

20:25
06/21/18
06/21
20:25
06/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$274.28

-1.72 (-0.62%)

, SPX

S&P 500

$0.00

(0.00%)

20:07
06/21/18
06/21
20:07
06/21/18
20:07
Periodicals
Money market funds pull the most funds since 2011, Reuters says »

Investors pulled $51B in…

SPY

SPDR S&P 500 ETF Trust

$274.28

-1.72 (-0.62%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANZBY

ANZ Banking

$0.00

(0.00%)

19:53
06/21/18
06/21
19:53
06/21/18
19:53
Hot Stocks
ANZ Bank doubles share buyback to AUD 3B »

ANZ announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$185.48

-1.06 (-0.57%)

, QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

19:50
06/21/18
06/21
19:50
06/21/18
19:50
Periodicals
Apple challenges four patents held by Qualcomm at USPTO, Bloomberg says »

Apple (AAPL) filed…

AAPL

Apple

$185.48

-1.06 (-0.57%)

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CS

Credit Suisse

$15.01

-0.2 (-1.31%)

19:42
06/21/18
06/21
19:42
06/21/18
19:42
Periodicals
Federal judge rules in Credit Suisse favor in a $300M broker suit, Reuters says »

A San Francisco federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$26.45

-0.8 (-2.94%)

, FUJIY

Fujifilm

$0.00

(0.00%)

19:19
06/21/18
06/21
19:19
06/21/18
19:19
Periodicals
Xerox judge rejects Fuji request to end deal vote injunction, Bloomberg says »

Fujifilm Holdings (FUJIY)…

XRX

Xerox

$26.45

-0.8 (-2.94%)

FUJIY

Fujifilm

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

19:11
06/21/18
06/21
19:11
06/21/18
19:11
Hot Stocks
Airbus says no-deal Brexit would lead to 'severe disruption' of U.K. production »

Airbus said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

, MDT

Medtronic

$86.29

0.11 (0.13%)

19:00
06/21/18
06/21
19:00
06/21/18
19:00
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Tandem Diabetes…

TNDM

TNDM

MDT

Medtronic

$86.29

0.11 (0.13%)

RHT

Red Hat

$165.62

-3.64 (-2.15%)

VMW

VMware

$152.08

-0.07 (-0.05%)

SPLK

Splunk

$113.06

-2.8 (-2.42%)

SGH

Smart Global

$39.79

-0.72 (-1.78%)

TCS

Container Store

$8.73

0.08 (0.92%)

LRCX

Lam Research

$176.01

1.54 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

  • 21

    Jun

  • 22

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 07

    Jul

  • 09

    Jul

  • 10

    Jul

  • 10

    Jul

  • 10

    Jul

  • 12

    Jul

  • 12

    Jul

  • 12

    Jul

BDRBF

Bombardier

$0.00

(0.00%)

, ERJ

Embraer

$25.48

-0.2 (-0.78%)

18:53
06/21/18
06/21
18:53
06/21/18
18:53
Periodicals
Bombardier sees CRJ 900 winning 'half or more' of market share, Reuters says »

Bombardier's (BDRBF)…

BDRBF

Bombardier

$0.00

(0.00%)

ERJ

Embraer

$25.48

-0.2 (-0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

  • 02

    Aug

WOW

WideOpenWest

$9.44

-0.2497 (-2.58%)

18:37
06/21/18
06/21
18:37
06/21/18
18:37
Initiation
WideOpenWest initiated at B. Riley FBR »

WideOpenWest initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CABO

Cable One

$716.20

-2.81 (-0.39%)

18:37
06/21/18
06/21
18:37
06/21/18
18:37
Initiation
Cable One initiated at B. Riley FBR »

Cable One initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

, DIS

Disney

$105.89

-1.39 (-1.30%)

18:32
06/21/18
06/21
18:32
06/21/18
18:32
Hot Stocks
Disney offers to divest Fox assets generating up to $1B in EBITDA »

In a regulatory filing,…

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

DIS

Disney

$105.89

-1.39 (-1.30%)

CMCSA

Comcast

$32.80

-0.595 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$86.29

0.11 (0.13%)

18:29
06/21/18
06/21
18:29
06/21/18
18:29
Hot Stocks
Medtronic announces FDA approval of MiniMed 670G system »

Medtronic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

AEO

American Eagle

$25.27

0.615 (2.49%)

18:23
06/21/18
06/21
18:23
06/21/18
18:23
Hot Stocks
American Eagle director Page sells 44,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,157.63

-11.75 (-1.00%)

, GOOGL

Alphabet Class A

$1,169.56

-14.27 (-1.21%)

18:19
06/21/18
06/21
18:19
06/21/18
18:19
Periodicals
YouTube to let content creators sell monthly subscriptions, Bloomberg says »

Google's YouTube is…

GOOG

Alphabet

$1,157.63

-11.75 (-1.00%)

GOOGL

Alphabet Class A

$1,169.56

-14.27 (-1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

NMR

Nomura

$4.85

-0.075 (-1.52%)

18:09
06/21/18
06/21
18:09
06/21/18
18:09
Periodicals
Nomura to cut 40 global markets traders in the U.S., Bloomberg says »

Nomura is expected to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$120.06

-0.2 (-0.17%)

18:02
06/21/18
06/21
18:02
06/21/18
18:02
Hot Stocks
SPDR Gold Trust holdings fall to 824.63MT from 828.76MT »

This is the first decline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.37

-0.13 (-0.24%)

17:50
06/21/18
06/21
17:50
06/21/18
17:50
Periodicals
Wells Fargo said to let go of 10 analysts to cut costs, Bloomberg reports »

Wells Fargo has laid off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

  • 12

    Apr

  • 16

    Jul

  • 15

    Oct

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

, DIS

Disney

$105.89

-1.39 (-1.30%)

17:47
06/21/18
06/21
17:47
06/21/18
17:47
Periodicals
Breaking Periodicals news story on 21st Century Fox, Disney, Comcast »

Disney to double asset…

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

DIS

Disney

$105.89

-1.39 (-1.30%)

CMCSA

Comcast

$32.80

-0.595 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENTA

Enanta

$118.81

3.54 (3.07%)

17:45
06/21/18
06/21
17:45
06/21/18
17:45
Conference/Events
Enanta management to meet with Oppenheimer »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

TNTR

Tintri

$0.20

0.0369 (22.38%)

17:32
06/21/18
06/21
17:32
06/21/18
17:32
Hot Stocks
Tintri receives Nasdaq noncompliance notice from 10-Q filing delay »

Tintri received a notice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUE

Cue Biopharma

$12.41

0.18 (1.47%)

17:25
06/21/18
06/21
17:25
06/21/18
17:25
Syndicate
Breaking Syndicate news story on Cue Biopharma »

Cue Biopharma files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.